Evaluation of published reports of foam sclerotherapy: what do we know conclusively?

被引:13
|
作者
Myers, K. A. [1 ]
Roberts, S. [1 ]
机构
[1] Victoria Vein Clin, Melbourne, Vic, Australia
关键词
foam sclerotherapy; varicose; veins; reticular; telangiectases; GREAT SAPHENOUS-VEIN; ULTRASOUND-GUIDED SCLEROTHERAPY; RANDOMIZED CONTROLLED-TRIAL; POLIDOCANOL FOAM; VARICOSE-VEINS; ENDOVENOUS LASER; DETERGENT SCLEROSANTS; EFFICACY; MICROEMBOLISM; STABILITY;
D O I
10.1258/phleb.2009.009048
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: The aim was to evaluate the published literature to assess what is conclusively known about optimal technique and outcome for foam sclerotherapy. Methods: A literature search was performed for randomised controlled trials, meta-analyses and observational studies using appropriate statistical techniques with survival analysis for long-term outcome. Results: Foam is more effective than liquid for ultrasound-guided sclerotherapy. Both sclerosants commonly used are equally effective for sclerotherapy for small veins. Ultrasound signals appear in the systemic circulation in most patients after foam sclerotherapy but do not appear to be associated with serious complications. Conclusion: Little else is known about the optimal preparation of foamed sclerosants and the best technique for administering foam for sclerotherapy. Long-term studies are required to determine outcome for various techniques. There is an opportunity for many controlled trials to assess results.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 50 条
  • [1] Treatment of cryptosporidiosis: do we know what we think we know?
    Cabada, Miguel M.
    White, A. Clinton, Jr.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (05) : 494 - 499
  • [2] Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
    Boziki, Marina Kleopatra
    Kesidou, Evangelia
    Theotokis, Paschalis
    Mentis, Alexios-Fotios A.
    Karafoulidou, Eleni
    Melnikov, Mikhail
    Sviridova, Anastasia
    Rogovski, Vladimir
    Boyko, Alexey
    Grigoriadis, Nikolaos
    BRAIN SCIENCES, 2020, 10 (04)
  • [3] Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie, Martin J.
    Ben-Menachem, Elinor
    EPILEPSIA, 2018, 59 (02) : 291 - 296
  • [4] O2, do we know what to do?
    Young, Paul J.
    Bagshaw, Sean M.
    Bailey, Michael
    Bellomo, Rinaldo
    Mackie, Diane
    Pilcher, David
    Landoni, Giovanni
    Nichol, Alistair
    Martin, Daniel
    CRITICAL CARE AND RESUSCITATION, 2019, 21 (04) : 230 - 232
  • [5] The side effects of phototherapy for neonatal jaundice: what do we know? What should we do?
    Xiong, Tao
    Qu, Yi
    Cambier, Stephanie
    Mu, Dezhi
    EUROPEAN JOURNAL OF PEDIATRICS, 2011, 170 (10) : 1247 - 1255
  • [6] Nutrition in emergencies: Do we know what works?
    Webb, Patrick
    Boyd, Erin
    de Pee, Saskia
    Lenters, Lindsey
    Bloem, Martin
    Schultink, Werner
    FOOD POLICY, 2014, 49 : 33 - 40
  • [7] Superior Capsule Reconstruction: What Do We Know?
    Dimock, Richard A. C.
    Malik, Sheraz
    Consigliere, Paolo
    Imam, Mohamed A.
    Narvani, A. Ali
    ARCHIVES OF BONE AND JOINT SURGERY-ABJS, 2019, 7 (01): : 3 - 11
  • [8] Psychotherapeutic interventions for cannabis use disorder. What do we know and what should we do?
    Pouliquen, M.
    Auriacombe, M.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2022, 48 (01): : 70 - 77
  • [9] What do we know about feline leishmaniosis?
    Alves Soares, Carla Sofia
    Duarte, Sofia Cancela
    Sousa, Sergio Ramalho
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2016, 18 (06) : 435 - 442
  • [10] Benign Paroxysmal Positional Vertigo: What We Do and Do Not Know
    Nuti, Daniele
    Zee, David S.
    Mandala, Marco
    SEMINARS IN NEUROLOGY, 2020, 40 (01) : 49 - 58